

Amendments to the Claim:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A peptide having a sequence of at most 44 amino acid residues comprising a motif of the formula

$X^1-X^2-Cys-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}-X^{13}-X^{14}-X^{15}-X^{16}-X^{17}-Cys-X^{18}-X^{19}$,

wherein

(1) each of X1 and X19 is, independently, either a sequence consisting of 2-5 amino acid residues or a single amino acid residue, and

(2) each of X2-X18 is, independently, a single amino acid residue, and

~~X can be an amino acid sequence or a single amino acid residue selected either from Group 1 consisting of Ala, Gly, and Ser, Group 2 consisting of Arg and Lys, Group 3 consisting of His, Ile, Leu, Met, Phe, Pro, Thr, Val, Trp, and Tyr,~~

~~Group 4 consisting of Asn and Gln, or~~

~~Group 5 consisting of Ala, Asn, Arg, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val,~~

wherein

~~X¹ can be represented by~~ is a sequence consisting of 2-5 amino acid residues, or an amino acid residue selected from Group 2;

~~X² is selected from Group 5~~ or Group 3;

~~X³, X¹⁵ and X⁴ are selected from Group 1;~~

~~X⁵ is Thr or selected from~~ from Group 1;

~~X⁶, X¹¹, X¹², X¹³ and X⁷ are selected from Group 3;~~

~~X⁸ and X¹⁷ are selected from Group 1, 3 or 4;~~

~~X⁹ is selected from~~ from Group 5, ~~1 or 3;~~

~~X¹⁰ is selected from~~ from Group 2, 3 or 4;

X¹⁴ is Ser or selected from ~~from~~ Group 3;

X¹⁶ and X¹⁸ is selected from Group 1 or 3;

X¹⁹ ~~can be represented by~~ is a sequence consisting of 2-5 amino acid residues, or a single amino acid residue selected from Group 5, 2, or 4,

with Group 1 consisting of Ala, Gly, and Ser,

Group 2 consisting of Arg and Lys,

Group 3 consisting of His, Ile, Leu, Met, Phe, Pro, Thr, Val, Trp, and Tyr,

Group 4 consisting of Asn and Gln, and

Group 5 consisting of Ala, Asn, Arg, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val;

with the proviso, that when X¹ includes Pro, then X¹⁹ is Gln, and wherein at least one of the following conditions applies:

(a) X¹⁹ is Arg or Ala,

(b) X⁹ is Pro, Arg, or Gln,

(c) X¹⁹ is Gln and X¹ includes Pro,

(d) X¹⁹ is 2-5 amino acid residues, or

(e) X¹⁰ is Asn or Gln.

2-26. (Cancelled)

27. (Previously Presented) The peptide according to claim 1, wherein said peptide has the sequence KQGRHFCCGALIHARFVMTAASCFR (SEQ ID NO: 595).

28. (Withdrawn) The peptide according to claim 1, wherein said peptide has the sequence KQGRPFCGGALIHARFVMTAASCFR (SEQ ID NO: 596).

29. (Withdrawn) The peptide according to claim 1, wherein said peptide has the sequence KQGRHFCCGALIHPRFVMTAASCFR (SEQ ID NO: 597).

30. (Withdrawn) The peptide according to claim 1, wherein said peptide has the sequence KQGRPFCGGALIHPRFVMTAASCFR (SEQ ID NO: 598).

31. (Withdrawn) The peptide according to claim 1, wherein

said peptide has the sequence RFCSAATLVFRPHVLGACFPRGQK (SEQ ID NO: 599).

32. (Withdrawn) The peptide according to claim 1, wherein said peptide has the sequence NQGRPFCAGALVHPRFVLTAASCFR (SEQ ID NO: 600).

33. (Withdrawn) The peptide according to claim 1, wherein said peptide has the sequence KQGRPFCAGALVHPRFVLTAASCFQ (SEQ ID NO: 601).

34. (Withdrawn) The peptide according to claim 1, wherein said peptide has the sequence NQGRPFCAGALVHPRFVLTAASCFQ (SEQ ID NO: 602).

35. (Withdrawn) The peptide according to claim 1, wherein said peptide has the sequence KQGRPFCAGALVHPQFVLTAASCFR (SEQ ID NO: 603).

36. (Withdrawn) The peptide according to claim 1, wherein said peptide has the sequence LRGGHFCGATLIAPNFVMSAAHCVA (SEQ ID NO: 604).

37. (Withdrawn) The peptide according to claim 1, wherein said peptide has the sequence RRGGHFCGATLIARNFVMSAVHCVN (SEQ ID NO: 605).

38. (Withdrawn) The peptide according to claim 1, wherein said peptide has the sequence RSREYRCGGTLVSQRYILTAASCAA (SEQ ID NO: 606).

39. (Cancelled)

40. (Withdrawn) The peptide according to claim 1, wherein said peptide has the sequence KQGRPFCAGALVHPRFVLTAASCFR (SEQ ID NO: 593).

41-52. (Cancelled)

53. (Previously Presented) The peptide according to claim 1, wherein said peptide is capable of inhibiting the secretion of cytokine IL-6 from monocytes.

54. (Withdrawn) The peptide according to claim 1, wherein said peptide is capable of stimulating the secretion of cytokine IL-6 from monocytes.

55-56. (Cancelled)

57. (Withdrawn-Currently Amended) A method of treatment of gram-negative bacterial infection comprising administering_L to an individual in need_L one or more peptides as defined in claim 1.

58. (Withdrawn-currently amended) A method of treatment of gram-positive bacterial infection comprising administering_L to an individual in need_L one or more peptides as defined in claim 1.

59-72. (Cancelled)

73. (Previously Presented) A pharmaceutical composition comprising a peptide as defined in claim 1.

74. (New) The peptide according to claim 1, wherein at least one of conditions (aa)-(dd) applies

(aa) X19 is Arg,

(bb) X19 is Pro,

(cc) X19 is Gln and X1 includes Pro, or

(dd) X19 is 2-5 amino acid residues.

75. (New) The peptide according to claim 1, wherein at least one of conditions (aa)-(cc) applies.

76. (New) The peptide according to claim 1, wherein at least condition (aa) applies.

77. (New) The peptide according to claim 1, wherein at least condition (bb) applies.

78. (New) The peptide according to claim 1, wherein at least condition (cc) applies.

79. (New) The peptide according to claim 1 wherein X10 is Asn or Gln.

80. (New) A method of treatment of gram-negative bacterial infection comprising administering, to an individual in need, one or more peptides as defined in claim 75.

81. (New) A method of treatment of gram-negative bacterial infection comprising administering, to an individual in need, one or more peptides as defined in claim 27.